{"id":"basal-insulin-only","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":"common","effect":"Weight gain"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"rare to uncommon","effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basal insulin mimics the body's natural basal insulin secretion by binding to insulin receptors on target tissues, facilitating glucose uptake and storage while suppressing gluconeogenesis. This long-acting formulation is designed to maintain stable insulin levels throughout the day and night, forming the foundation of insulin therapy in type 1 and type 2 diabetes management.","oneSentence":"Basal insulin provides a steady, long-acting background level of insulin to regulate fasting blood glucose and suppress hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:29.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06716424","phase":"PHASE4","title":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-06","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT06280703","phase":"PHASE1","title":"A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-05-15","conditions":"Healthy, Type 1 Diabetes Mellitus","enrollment":118},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT04952779","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-02","conditions":"Diabetes Mellitus, Type 2","enrollment":750},{"nctId":"NCT07284511","phase":"PHASE2, PHASE3","title":"A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar","status":"NOT_YET_RECRUITING","sponsor":"Melissa-Rosina Pasqua","startDate":"2026-01-05","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D","enrollment":105},{"nctId":"NCT06776094","phase":"NA","title":"Physical Activity and Insulin Sensitivity Dynamics","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2025-05-05","conditions":"Insulin Sensitivity","enrollment":8},{"nctId":"NCT01648478","phase":"NA","title":"IRAPs (Secreted Insulin Regulated AminoPeptidase): a New Insulin Sensitivity Biomarker","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2012-06","conditions":"Insulin Resistance","enrollment":21},{"nctId":"NCT06238778","phase":"PHASE2","title":"Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diasome Pharmaceuticlas, Inc.","startDate":"2024-01-23","conditions":"Diabetes Mellitus, Type 1","enrollment":227},{"nctId":"NCT05691712","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-02-05","conditions":"Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders","enrollment":257},{"nctId":"NCT06616779","phase":"","title":"DigiDiab Evaluation Domiciliary Nursing Care","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2024-11-30","conditions":"Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Insulin Requiring","enrollment":40},{"nctId":"NCT06406439","phase":"NA","title":"DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients","status":"COMPLETED","sponsor":"G2e Co., Ltd","startDate":"2024-05-21","conditions":"Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus","enrollment":120},{"nctId":"NCT07004153","phase":"NA","title":"A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"G2e Co., Ltd","startDate":"2025-06","conditions":"Diabetes Mellitus","enrollment":152},{"nctId":"NCT06966427","phase":"NA","title":"Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections","status":"RECRUITING","sponsor":"Rabin Medical Center","startDate":"2025-05-08","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":45},{"nctId":"NCT06424652","phase":"NA","title":"Effect of Physiologic Insulin Administration on Cognition","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2024-05-16","conditions":"Alzheimer Disease","enrollment":1},{"nctId":"NCT04617795","phase":"NA","title":"Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2020-11-23","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT02496780","phase":"PHASE2, PHASE3","title":"The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":65},{"nctId":"NCT05159453","phase":"PHASE2, PHASE3","title":"Dose Response Study of Transdermal Human Insulin in Patients","status":"NOT_YET_RECRUITING","sponsor":"Transdermal Delivery Solutions Corp","startDate":"2025-09-02","conditions":"Glucose, High Blood","enrollment":30},{"nctId":"NCT06487598","phase":"NA","title":"To Evaluate add-on Effect of Nisha-Amalaki Tablets Along With Insulin on Glycemic Control in Type 1 Diabetes Patients (RCTNA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hirabai Cowasji Jehangir Medical Research Institute","startDate":"2024-07-01","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT06600776","phase":"PHASE4","title":"Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-10-06","conditions":"Type 1 Diabetes (T1D)","enrollment":50},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT03804983","phase":"NA","title":"Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2019-01-15","conditions":"Type 1 Diabetes Mellitus","enrollment":22},{"nctId":"NCT05111301","phase":"NA","title":"Control-IQ Technology in Individuals With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tandem Diabetes Care, Inc.","startDate":"2021-11-30","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":30},{"nctId":"NCT03455985","phase":"NA","title":"Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low","enrollment":158},{"nctId":"NCT04678661","phase":"NA","title":"My Dose Coach Mobile App to Support Insulin Titration and Maintenance","status":"TERMINATED","sponsor":"Linda Siminerio","startDate":"2021-02-15","conditions":"Diabetes Mellitus Type 2 - Insulin-Treated","enrollment":60},{"nctId":"NCT03449251","phase":"PHASE2","title":"A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2018-03-28","conditions":"Cardiovascular Diseases, Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03660553","phase":"PHASE4","title":"Simplified Insulin Regimen for the Elderly","status":"TERMINATED","sponsor":"University of Miami","startDate":"2018-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":7},{"nctId":"NCT03195140","phase":"NA","title":"Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial","status":"COMPLETED","sponsor":"Tandem Diabetes Care, Inc.","startDate":"2017-08-11","conditions":"Diabetes Mellitus, Type 1","enrollment":103},{"nctId":"NCT05199714","phase":"NA","title":"A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-02-21","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT05262595","phase":"PHASE1","title":"A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-03","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT06074913","phase":"NA","title":"Early Warning of Diabetic Peripheral Neuropathy by Using Infrared Thermography and the Effectiveness of Electroacupuncture in Its Prevention","status":"UNKNOWN","sponsor":"Zhejiang Chinese Medical University","startDate":"2023-07-07","conditions":"Diabetic Peripheral Neuropathy","enrollment":200},{"nctId":"NCT05067270","phase":"PHASE1","title":"A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-22","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT04849845","phase":"PHASE4","title":"Afrezza® Dosing Optimization Study","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-04-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT00788840","phase":"PHASE4","title":"Detemir Energy Expenditure Study","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":30},{"nctId":"NCT01779362","phase":"PHASE3","title":"RISE Adult Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-04","conditions":"Prediabetes, Type 2 Diabetes","enrollment":267},{"nctId":"NCT01779375","phase":"PHASE3","title":"RISE Pediatric Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-06-16","conditions":"Prediabetes, Type 2 Diabetes","enrollment":91},{"nctId":"NCT03720080","phase":"","title":"The OpenAPS_ShadowMode Study","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2019-05-16","conditions":"Type1diabetes","enrollment":10},{"nctId":"NCT03093636","phase":"NA","title":"Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2017-04-17","conditions":"Type1 Diabetes Mellitus","enrollment":80},{"nctId":"NCT05324462","phase":"","title":"Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 2","enrollment":175},{"nctId":"NCT05429359","phase":"NA","title":"cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2022-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT02967237","phase":"PHASE4","title":"Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-04","conditions":"Diabetes Mellitus, Type 2","enrollment":136},{"nctId":"NCT03760991","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-12-18","conditions":"Type 2 Diabetes Mellitus","enrollment":372},{"nctId":"NCT03406000","phase":"PHASE4","title":"Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-22","conditions":"Type I Diabetes Mellitus","enrollment":170},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT04533945","phase":"NA","title":"Feasibility of Using the CGM During TOC From in Persons With T2D Using Insulin","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-03-25","conditions":"Diabetes, Type 2 Diabetes","enrollment":40},{"nctId":"NCT04834362","phase":"PHASE4","title":"Insulin for Hyperglycemia in Stroke Trial","status":"COMPLETED","sponsor":"National Institute of Neurosciences and Hospital, Dhaka","startDate":"2021-04-05","conditions":"Hyperglycemia, Stroke, Acute","enrollment":452},{"nctId":"NCT03713684","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-11-09","conditions":"Type 2 Diabetes Mellitus","enrollment":370},{"nctId":"NCT05001815","phase":"NA","title":"CSII Versus MDI in Pregnant Women With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-12-15","conditions":"Type 2 Diabetes, Pregnancy in Diabetic","enrollment":80},{"nctId":"NCT04323462","phase":"PHASE4","title":"Intensive Glycemic Control For Diabetic Foot Ulcer Healing","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-01","conditions":"Diabetic Foot Ulcer","enrollment":326},{"nctId":"NCT01555788","phase":"NA","title":"DiaPort Closed-Loop Artificial Pancreas","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2012-02","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT03285594","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-09-15","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT02527265","phase":"PHASE2","title":"Afrezza Safety and Pharmacokinetics Study in Pediatric Patients","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2017-09-28","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT04542213","phase":"PHASE3","title":"Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19","status":"COMPLETED","sponsor":"Hospital Regional de Alta Especialidad del Bajio","startDate":"2020-08-01","conditions":"Hyperglycemia, Covid19","enrollment":70},{"nctId":"NCT04409587","phase":"PHASE4","title":"Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump","status":"COMPLETED","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2018-04-12","conditions":"Type1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT02192424","phase":"PHASE3","title":"Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":109},{"nctId":"NCT02634528","phase":"PHASE1","title":"Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal","status":"COMPLETED","sponsor":"Julphar Gulf Pharmaceutical Industries","startDate":"2016-11-16","conditions":"Diabetes Mellitus","enrollment":85},{"nctId":"NCT02752412","phase":"PHASE3","title":"Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-17","conditions":"Type 2 Diabetes Mellitus","enrollment":513},{"nctId":"NCT03424044","phase":"PHASE1","title":"Three Way Crossover Closed Loop Study With Xeris Glucagon","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2018-03-29","conditions":"Type1diabetes","enrollment":23},{"nctId":"NCT04383015","phase":"NA","title":"Carbohydrate and Insulin Requirements During Prolonged Fasted Exercise","status":"COMPLETED","sponsor":"York University","startDate":"2018-10-31","conditions":"Type 1 Diabetes","enrollment":15},{"nctId":"NCT02320721","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1014},{"nctId":"NCT02814123","phase":"PHASE2","title":"Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University","startDate":"2017-01-13","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT04237129","phase":"PHASE1","title":"PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2019-08-27","conditions":"Diabetes Mellitus, Type 1","enrollment":36},{"nctId":"NCT04235439","phase":"PHASE1","title":"PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2019-04-23","conditions":"Diabetes Mellitus","enrollment":36},{"nctId":"NCT04125082","phase":"PHASE4","title":"A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections","status":"UNKNOWN","sponsor":"Diabetes and Glandular Disease Clinic","startDate":"2019-02-27","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":29},{"nctId":"NCT01170208","phase":"NA","title":"Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2010-06","conditions":"Diabetes, Insulin","enrollment":46},{"nctId":"NCT04236895","phase":"PHASE1","title":"PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2018-07-10","conditions":"Diabetes Mellitus, Type 1","enrollment":114},{"nctId":"NCT04013919","phase":"","title":"Observational, Data Collection Study for Subjects With Diabetes Using Insulin Injections","status":"UNKNOWN","sponsor":"DreaMed Diabetes","startDate":"2019-09-20","conditions":"Diabetes Mellitus","enrollment":260},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT02305381","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-12-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":397},{"nctId":"NCT03970668","phase":"","title":"Linagliptin in Post-renal Transplantation","status":"COMPLETED","sponsor":"Universidad de Guanajuato","startDate":"2016-01-01","conditions":"Transplanted Kidney Complication","enrollment":28},{"nctId":"NCT03025009","phase":"PHASE1","title":"A Study of LY3192767 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-03-06","conditions":"Healthy","enrollment":57},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT01995526","phase":"PHASE1","title":"A Study of Insulin Peglispro in Healthy Male Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-12","conditions":"Healthy Volunteers","enrollment":11},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT02862730","phase":"NA","title":"Four Way Crossover Closed Loop With Exercise Detection","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2016-10","conditions":"Type 1 Diabetes","enrollment":25},{"nctId":"NCT02059174","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-10","conditions":"Type 1 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02287532","phase":"NA","title":"Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen","status":"COMPLETED","sponsor":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète","startDate":"2013-02","conditions":"Diabetes","enrollment":667},{"nctId":"NCT01281605","phase":"NA","title":"Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2011-01","conditions":"Type 2 Diabetes","enrollment":181},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT02706119","phase":"PHASE4","title":"Insulin in Total Parenteral Nutrition","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2016-07-01","conditions":"Diabetes Mellitus","enrollment":163},{"nctId":"NCT01790438","phase":"PHASE3","title":"A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Diabetes Mellitus, Type 2","enrollment":641},{"nctId":"NCT03335501","phase":"PHASE2","title":"Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-04-01","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT01582451","phase":"PHASE3","title":"A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":466},{"nctId":"NCT01572740","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-04-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":257},{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02104804","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-07","conditions":"Type 2 Diabetes Mellitus","enrollment":953},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT03112538","phase":"PHASE4","title":"Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy","status":"UNKNOWN","sponsor":"Clinical Research Centre, Malaysia","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":118},{"nctId":"NCT02767596","phase":"PHASE4","title":"Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog","status":"TERMINATED","sponsor":"Laniado Hospital","startDate":"2016-07-12","conditions":"Diabetes Mellitus Type 2","enrollment":2},{"nctId":"NCT00509925","phase":"PHASE4","title":"Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-07","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":23},{"nctId":"NCT00184600","phase":"PHASE3","title":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT02811484","phase":"PHASE4","title":"Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2016-06","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01308164","phase":"NA","title":"MD Logic Pump Advisor -Pediatric Study","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2011-03","conditions":"Type 1 Diabetes","enrollment":25},{"nctId":"NCT02282254","phase":"PHASE2","title":"Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2014-10","conditions":"Type 1 Diabetes","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Basal insulin glargine"],"phase":"phase_3","status":"active","brandName":"Basal insulin only","genericName":"Basal insulin only","companyName":"Mount Sinai Hospital, Canada","companyId":"mount-sinai-hospital-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Basal insulin is used to treat conditions such as Type 1 Diabetes, Type 2 Diabetes, and Pregnancy in Diabetic, and it works by acting as an insulin receptor agonist. It is administered through various methods, including insulin pump therapy, and has been studied in clinical trials for its effectiveness in managing glucose levels.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}